---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-05-10T19:00:31.449011'
end_time: '2026-05-10T19:19:50.426527'
duration_seconds: 1158.98
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BTF3
  gene_symbol: BTF3
  uniprot_accession: P20290
  protein_description: 'RecName: Full=Transcription factor BTF3; AltName: Full=Nascent
    polypeptide-associated complex subunit beta; Short=NAC-beta; AltName: Full=RNA
    polymerase B transcription factor 3;'
  gene_info: Name=BTF3; Synonyms=NACB; ORFNames=OK/SW-cl.8;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the NAC-beta family. .
  protein_domains: BTF3. (IPR039370); NAC_A/B_dom_sf. (IPR038187); Nas_poly-pep-assoc_cplx_dom.
    (IPR002715); NAC (PF01849)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 23
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P20290
- **Protein Description:** RecName: Full=Transcription factor BTF3; AltName: Full=Nascent polypeptide-associated complex subunit beta; Short=NAC-beta; AltName: Full=RNA polymerase B transcription factor 3;
- **Gene Information:** Name=BTF3; Synonyms=NACB; ORFNames=OK/SW-cl.8;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the NAC-beta family. .
- **Key Domains:** BTF3. (IPR039370); NAC_A/B_dom_sf. (IPR038187); Nas_poly-pep-assoc_cplx_dom. (IPR002715); NAC (PF01849)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BTF3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BTF3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BTF3** (gene ID: BTF3, UniProt: P20290) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P20290
- **Protein Description:** RecName: Full=Transcription factor BTF3; AltName: Full=Nascent polypeptide-associated complex subunit beta; Short=NAC-beta; AltName: Full=RNA polymerase B transcription factor 3;
- **Gene Information:** Name=BTF3; Synonyms=NACB; ORFNames=OK/SW-cl.8;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the NAC-beta family. .
- **Key Domains:** BTF3. (IPR039370); NAC_A/B_dom_sf. (IPR038187); Nas_poly-pep-assoc_cplx_dom. (IPR002715); NAC (PF01849)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BTF3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BTF3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BTF3** (gene ID: BTF3, UniProt: P20290) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Research report: Human **BTF3** (UniProt **P20290**) — functional annotation and current understanding

### 0) Target verification (critical identity check)
The literature synthesized below pertains to **human BTF3** (Basic Transcription Factor 3), which is also known as **NAC-beta / NACB**, the beta subunit of the **nascent polypeptide-associated complex (NAC)**. Multiple peer-reviewed sources explicitly equate **BTF3 = NAC-beta/NACB** and describe the complex as a heterodimer with **NACA (NAC-alpha)**, matching the UniProt description and NAC-beta family/domain context. (zheng2022thenascentpolypeptideassociated pages 1-2, wang2021molecularcharacterizationof pages 1-2)

---

### 1) Key concepts and definitions (current understanding)

#### 1.1 BTF3 as **NAC-beta (NACB)**: a ribosome-associated chaperone/triage factor
**NAC (nascent polypeptide-associated complex)** is a ribosome-associated complex positioned at/near the **ribosome exit tunnel** and composed of **NACA (alpha)** and **BTF3/NACB (beta)**. Structural evidence discussed in a high-quality mechanistic study places the **BTF3 N-terminal tail within the exit tunnel**, supporting a direct physical relationship between BTF3-containing NAC and emerging nascent chains. (zheng2022thenascentpolypeptideassociated pages 1-2)

NAC/BTF3 is described as interacting with short nascent peptide sequences, “escorting” emerging chains, and modulating how nascent chains engage other ribosome-associated factors such as **signal recognition particle (SRP)** and **methionine aminopeptidase**; NAC also has described chaperone/anti-aggregation functions. (zheng2022thenascentpolypeptideassociated pages 1-2)

A representative schematic showing NAC associated with a translating ribosome and the tunnel-proximal NAC tail is available (Figure schematic) and supports this spatial model of NAC action at the exit tunnel. (zheng2022thenascentpolypeptideassociated media 2bfdbb98)

#### 1.2 BTF3 as a **transcription factor (historical and cancer-mechanism contexts)**
BTF3 has also been described as a transcription factor that can initiate transcription via promoter elements, with isoform-specific activity (BTF3a transcriptionally active; BTF3b inactive) in prior literature summarized in a mechanistic cancer study. (wang2021molecularcharacterizationof pages 1-2)

In colorectal cancer mechanistic work, BTF3 was directly studied **both** as a transcription factor and as part of the NAC complex; this dual framing is consistent with broad evidence that BTF3 can participate in nuclear transcriptional regulation while also being a ribosome-associated NAC subunit. (wang2021molecularcharacterizationof pages 2-4)

---

### 2) Molecular functions, subcellular localization, and pathway placement (evidence-focused)

#### 2.1 Subcellular localization: cytosolic ribosome/exit-tunnel association versus nuclear transcriptional role
**Ribosome-associated localization (NAC role).** NAC is described as being present at the **ribosome exit tunnel** with structural placement of the BTF3 tail in the tunnel, directly implying a primarily **cytosolic ribosome-associated** functional context for BTF3 in its NAC role. (zheng2022thenascentpolypeptideassociated pages 1-2)

**Evidence consistent with ribosome/ER targeting functions.** In a colorectal cancer study using BTF3 immunoprecipitation-mass spectrometry (IP–MS), gene ontology enrichments among BTF3-associated proteins included **cytosolic ribosome** and **protein targeting to the ER**, consistent with established NAC functions in cotranslational triage and targeting control. (wang2021molecularcharacterizationof pages 6-7)

**Nuclear/transcriptional role.** The same colorectal cancer work investigated BTF3 transcriptional targets using combined **RNA-seq + ChIP-seq** and targeted ChIP assays, supporting a nuclear mode of action for at least a subset of BTF3 function in that context. (wang2021molecularcharacterizationof pages 2-4)

#### 2.2 Core interaction partners and complexes
**BTF3–NACA interaction (NAC heterodimer).** In colorectal cancer work, BTF3 is explicitly treated as a NAC subunit, and **NACA** was identified as a **BTF3-binding partner** in BTF3 IP–MS. (wang2021molecularcharacterizationof pages 6-7)

**Broad interaction landscape.** BTF3 IP–MS identified **542 BTF3-associated proteins**, and enrichment analyses spanned ribosomal/ER-targeting annotations as well as nuclear/DNA-binding-associated annotations, supporting a multi-compartment functional footprint in cancer cell contexts. (wang2021molecularcharacterizationof pages 6-7)

#### 2.3 Processes and pathways
**Cotranslational quality control / nascent-chain triage.** NAC/BTF3 is described as interacting with nascent peptides and shielding them from proteolysis or inappropriate interactions, and modulating interactions with SRP and other ribosome-associated factors. (zheng2022thenascentpolypeptideassociated pages 1-2)

**Translation initiation regulation in cis.** A mechanistic NAC study reports that NAC controls translation initiation in cis (via nucleolin recruitment mechanisms), linking the BTF3-containing NAC complex to translational regulation rather than only cotranslational chaperoning. (zheng2022thenascentpolypeptideassociated pages 8-8, zheng2022thenascentpolypeptideassociated pages 1-2)

**ER targeting prevention.** Prior work summarized in colorectal cancer mechanistic context states that binding of BTF3 with NACA helps prevent inappropriate targeting of non-secretory nascent polypeptides to the ER. (wang2021molecularcharacterizationof pages 1-2)

---

### 3) Recent developments and latest research (prioritizing 2023–2024)

#### 3.1 Hepatocellular carcinoma (HCC): BTF3 → FOXM1 → GLUT1 axis (metabolic reprogramming)
A 2023 peer-reviewed study in *Cancer Biology & Therapy* (June 2023; https://doi.org/10.1080/15384047.2023.2225884) reports BTF3 upregulation in HCC and presents functional evidence that BTF3 promotes **proliferation and glycolysis** via a **FOXM1/GLUT1 axis**. BTF3 knockdown reduced proliferation and multiple glycolysis-associated readouts (e.g., ECAR, glucose consumption, lactate production), and FOXM1 overexpression rescued these effects; a **direct interaction** between BTF3 and FOXM1 was supported by luciferase and co-IP assays. (wang2023btf3promotesproliferation pages 1-2, wang2023btf3promotesproliferation pages 2-3)

#### 3.2 HCC: BTF3 transcriptionally upregulates PDCD2L and restrains p53 signaling
A 2024 peer-reviewed study in *Molecular Medicine* (December 2024; https://doi.org/10.1186/s10020-024-01044-x) reports that BTF3 is upregulated in HCC and that high BTF3 expression is associated with poorer prognosis based on TCGA and ICGC analyses (qualitative in accessible excerpts). Mechanistically, BTF3 is reported to **transcriptionally upregulate PDCD2L**, with PDCD2L restraining the **p53 pathway**, forming a proposed **BTF3/PDCD2L/p53 axis**. The study identifies **680 genes positively correlated with BTF3** using a correlation coefficient threshold **> 0.5**, and used ChIP/qRT-PCR and promoter luciferase assays to support promoter-level regulation. (kong2024btf3affectshepatocellular pages 1-2, kong2024btf3affectshepatocellular pages 12-13)

#### 3.3 Antiphospholipid syndrome (APS) monocyte models: BTF3/STAT3 complex drives NLRP3 pyroptosis/apoptosis
A 2024 peer-reviewed study in *Clinical and Translational Medicine* (January 2024; https://doi.org/10.1002/ctm2.1539) describes an epigenetic-to-inflammatory mechanism in APS models in which **LINC01128 promotes formation of a BTF3/STAT3 complex**, enhancing **STAT3 phosphorylation**, and (via p-STAT3 promoter binding) upregulating **NLRP3** to drive pyroptosis/apoptosis programs. Evidence included RNA pull-down/mass spectrometry, RIP, ChIRP, co-IP, and ChIP-qPCR for promoter occupancy, with functional validation in THP-1 cells, primary monocytes, and a β2GPI-induced mouse model. (tan2024arid5b‐mediatedlinc01128epigenetically pages 1-3, tan2024arid5b‐mediatedlinc01128epigenetically pages 13-16, tan2024arid5b‐mediatedlinc01128epigenetically pages 6-8)

#### 3.4 Multi-omics and proteomic signatures (2024): BTF3 in CLL protein deregulation
A 2024 peer-reviewed *Journal of Personalized Medicine* analysis (August 2024; https://doi.org/10.3390/jpm14080831) integrating proteomics and survival datasets in chronic lymphocytic leukemia (CLL) reports BTF3 among top upregulated proteins (listed within the top five). Kaplan–Meier analyses were performed; the authors state BTF3 “seems to affect survival only during the initial days of disease development” (no hazard ratio or p-value for BTF3 was present in retrieved excerpts). (mavridou2024integrativeanalysisof pages 7-10, mavridou2024integrativeanalysisof pages 5-7)

---

### 4) Current applications and real-world implementations

#### 4.1 Biomarker and prognostic-marker exploration in cancer
Across cancers, BTF3 is frequently assessed as an overexpressed gene/protein associated with disease progression, with mechanistic studies (e.g., HCC PDCD2L/p53; HCC FOXM1/GLUT1 glycolysis; CRC p53-regulatory hypotheses) providing biological rationale for its evaluation as a biomarker or target. (kong2024btf3affectshepatocellular pages 1-2, wang2023btf3promotesproliferation pages 1-2, wang2021molecularcharacterizationof pages 6-7)

However, in the retrieved excerpts, common clinical-performance statistics (AUC, hazard ratios with confidence intervals) were generally not available; therefore, this report refrains from asserting specific performance metrics beyond what is explicitly stated in accessible texts. (kong2024btf3affectshepatocellular pages 1-2, mavridou2024integrativeanalysisof pages 7-10)

#### 4.2 Drug repurposing and pathway-targeting implications: TNBC example
A 2024 *Scientific Reports* study (December 2024; https://doi.org/10.1038/s41598-024-79789-y) examining dapivirine in MDA-MB-231 triple-negative breast cancer (TNBC) found BTF3 downregulation in proteomic profiling and linked this to potential effects on “stem-like” tumor cell populations; the authors proposed that limited bioavailability might be addressed using delivery strategies such as antibody–drug conjugates or nanoparticle approaches. Quantitatively, the proteomics table reported BTF3 downregulation with a fold-change of **−1.8** (minus indicating downregulation). (patil2024multifacetedimpactof pages 13-14, patil2024multifacetedimpactof pages 7-10)

---

### 5) Expert interpretation and analysis (grounded in cited sources)

#### 5.1 Reconciling “transcription factor” and “ribosome chaperone” roles
A consistent theme is that **BTF3 is mechanistically anchored in ribosome biology** through its identity as **NAC-beta**, with structural placement at the exit tunnel and direct nascent-chain engagement supporting a core role in cotranslational triage and translation-linked regulation. (zheng2022thenascentpolypeptideassociated pages 1-2)

In parallel, multiple cancer-mechanism studies operationalize BTF3 as a **transcriptional regulator** (ChIP-seq-defined targets; promoter luciferase; transcriptional upregulation of PDCD2L), indicating that in disease states BTF3’s functional readouts can be nuclear and promoter-centric. (wang2021molecularcharacterizationof pages 2-4, kong2024btf3affectshepatocellular pages 12-13)

One plausible synthesis—consistent with the evidence but not claiming more than the data support—is that BTF3 may exert context-dependent functions: as a constitutive NAC subunit at ribosomes and as a transcriptional regulator in specific cellular programs (especially cancer). (wang2021molecularcharacterizationof pages 6-7, zheng2022thenascentpolypeptideassociated pages 1-2)

#### 5.2 Mechanistic breadth inferred from interactomes
The CRC IP–MS dataset’s 542 interactors and enrichment across ribosomal/ER-targeting and nuclear annotations suggest BTF3 participates in broad protein networks rather than a single linear pathway. Such breadth supports why diverse downstream phenotypes (glycolysis, apoptosis, EMT, inflammatory pyroptosis) can appear in different contexts when BTF3 is perturbed. (wang2021molecularcharacterizationof pages 6-7, wang2023btf3promotesproliferation pages 1-2, tan2024arid5b‐mediatedlinc01128epigenetically pages 13-16)

---

### 6) Relevant statistics and data points (from retrieved studies)
- **TNBC proteomics**: BTF3 downregulated with fold-change **−1.8** after dapivirine treatment (MDA-MB-231 cells). (patil2024multifacetedimpactof pages 7-10)
- **CRC clinical associations**: BTF3 associated with lymphatic invasion (**p = 0.000**) and pathologic stage (**p = 0.041**) in the reported cohort analysis. (wang2021molecularcharacterizationof pages 6-7)
- **HCC correlated genes**: 2024 HCC study reports **680 genes** positively correlated with BTF3 using correlation coefficient threshold **> 0.5**. (kong2024btf3affectshepatocellular pages 1-2)
- **CLL multi-omics**: BTF3 listed among top upregulated proteins and evaluated in survival analysis; described as affecting survival only in early disease days (no numeric HR/p in excerpt). (mavridou2024integrativeanalysisof pages 5-7)

---

### 7) Evidence summary table
The following table consolidates functions, mechanisms, experimental evidence types, localization implications, and source details.

| Functional aspect | Key evidence (brief) | Experimental approach | Subcellular localization implication | Source with year and URL/DOI | Citation ID |
|---|---|---|---|---|---|
| NAC/ribosome | Human BTF3 is explicitly identified as NAC-beta/NACB, the beta subunit of the nascent polypeptide-associated complex with NACA; NAC is positioned at the ribosome exit tunnel and BTF3’s N-terminal tail extends into the tunnel. | Structural/crystallography evidence cited in review-style mechanistic discussion; biochemical NAC literature synthesis. | Cytosolic, ribosome-exit-tunnel-associated. | Zheng et al., 2022, *Nucleic Acids Research*; https://doi.org/10.1093/nar/gkac751 | (zheng2022thenascentpolypeptideassociated pages 1-2) |
| Translation initiation control | NAC controls translation initiation in cis by recruiting nucleolin to the encoding mRNA after nascent peptide sensing; this establishes BTF3-containing NAC as a translation-regulatory complex. | Translation inhibition assays, RNA/protein interaction assays, mechanistic cell biology in NAC study. | Ribosome-associated cytosol; functionally linked to translating mRNPs. | Zheng et al., 2022, *Nucleic Acids Research*; https://doi.org/10.1093/nar/gkac751 | (zheng2022thenascentpolypeptideassociated pages 1-2, zheng2022thenascentpolypeptideassociated pages 8-8) |
| Nascent-chain chaperone | NAC/BTF3 binds short nascent peptide sequences, escorts emerging chains, shields them from proteolysis, and modulates access of other ribosome-associated factors. | Structural studies cited plus mechanistic biochemical evidence from NAC field summarized in paper. | Ribosome exit tunnel / nascent-chain interface in cytosol. | Zheng et al., 2022, *Nucleic Acids Research*; https://doi.org/10.1093/nar/gkac751 | (zheng2022thenascentpolypeptideassociated pages 1-2) |
| ER targeting prevention | BTF3-NACA binding prevents inappropriate targeting of non-secretory nascent polypeptides from ribosomes to the ER. | Prior mechanistic studies cited; CRC review/introduction summarizes established NAC function. | Cytosolic ribosome surface with consequences for ER targeting. | Wang et al., 2021, *Frontiers in Cell and Developmental Biology*; https://doi.org/10.3389/fcell.2020.601502 | (wang2021molecularcharacterizationof pages 1-2) |
| Transcription factor activity | BTF3 is described as a transcription factor that initiates transcription via promoter elements; BTF3a is transcriptionally active whereas BTF3b is inactive. In CRC, ChIP/ChIP-seq identified transcriptional targets including CHD1L. | ChIP-seq, targeted ChIP, RNA-seq integration; promoter-binding analysis. | Nuclear localization/function in transcriptional regulation. | Wang et al., 2021, *Frontiers in Cell and Developmental Biology*; https://doi.org/10.3389/fcell.2020.601502 | (wang2021molecularcharacterizationof pages 1-2, wang2021molecularcharacterizationof pages 2-4) |
| NAC complex interactions and dual localization | IP-MS identified NACA as a BTF3 interactor and 542 BTF3-associated proteins; enrichment implicated cytosolic ribosome, protein targeting to ER, RNA binding, and nuclear DNA-binding proteins, supporting dual NAC and transcription roles. | BTF3 immunoprecipitation-mass spectrometry, GO enrichment, interaction network analysis. | Supports both cytosolic/ribosomal/ER-associated and nuclear roles. | Wang et al., 2021, *Frontiers in Cell and Developmental Biology*; https://doi.org/10.3389/fcell.2020.601502 | (wang2021molecularcharacterizationof pages 6-7) |
| Cancer mechanism: FOXM1/GLUT1 glycolysis axis | In HCC, BTF3 is upregulated and promotes proliferation and glycolysis by increasing FOXM1 and GLUT1; BTF3 directly interacts with FOXM1, and FOXM1 overexpression rescues the effects of BTF3 knockdown. | RT-qPCR, western blot, dual-luciferase reporter, co-IP, shRNA knockdown, EdU/CCK-8, Seahorse ECAR, xenograft. | Primarily functional evidence in tumor cells; consistent with transcription-related nuclear activity plus broader cellular expression. | Wang et al., 2023, *Cancer Biology & Therapy*; https://doi.org/10.1080/15384047.2023.2225884 | (wang2023btf3promotesproliferation pages 1-2, wang2023btf3promotesproliferation pages 2-3) |
| Cancer mechanism: PDCD2L/p53 axis | In HCC, BTF3 transcriptionally upregulates PDCD2L, which restrains p53 signaling; BTF3 knockdown reduces proliferation and increases apoptosis, supporting an oncogenic BTF3/PDCD2L/p53 axis. | ChIP/qRT-PCR, dual-luciferase promoter assays, knockdown, apoptosis/proliferation assays, IHC, xenografts, TCGA/ICGC analyses. | Strongly supports nuclear transcriptional action in cancer cells. | Kong et al., 2024, *Molecular Medicine*; https://doi.org/10.1186/s10020-024-01044-x | (kong2024btf3affectshepatocellular pages 1-2, kong2024btf3affectshepatocellular pages 12-13) |
| p53 ubiquitination via HERC2 | CRC study proposed that BTF3 may inhibit or modulate HERC2-mediated p53 ubiquitination/degradation; HERC2 emerged repeatedly in E3-ligase analyses and prior literature links BTF3 to p53 stabilization. | IP-MS context plus E3 ligase prediction/analysis (Ubibrowser, iUUCD); literature-supported mechanism. | More consistent with regulatory/nuclear signaling effects than a purely ribosomal role. | Wang et al., 2021, *Frontiers in Cell and Developmental Biology*; https://doi.org/10.3389/fcell.2020.601502 | (wang2021molecularcharacterizationof pages 6-7) |
| miRNA regulation | miR-497-5p negatively regulates BTF3 in CRC; decreased miR-497-5p expression contributes to elevated BTF3. | Bioinformatic prediction, GEO dataset comparison, mimic transfection in HT29 cells, qPCR/validation. | Post-transcriptional regulation of BTF3 expression; no unique compartment implication beyond cellular mRNA regulation. | Wang et al., 2021, *Frontiers in Cell and Developmental Biology*; https://doi.org/10.3389/fcell.2020.601502 | (wang2021molecularcharacterizationof pages 6-7) |


*Table: This table summarizes the best-supported functional annotations for human BTF3/NAC-beta, integrating its ribosome-associated NAC biology, transcription-related activities, and cancer-linked mechanisms. It also maps each function to the main experimental approaches, localization implications, and source citations.*

---

### 8) Limitations of this synthesis
- Several retrieved 2023–2024 papers referenced survival/prognostic associations but did not expose explicit numeric effect sizes (e.g., hazard ratios, AUCs) in the available text excerpts; this report therefore limits quantitative claims to values explicitly present (e.g., fold-change −1.8; p-values; correlation threshold >0.5). (patil2024multifacetedimpactof pages 7-10, kong2024btf3affectshepatocellular pages 1-2, mavridou2024integrativeanalysisof pages 5-7)
- Some mechanistic NAC localization claims rely on structural evidence cited within a 2022 mechanistic paper rather than newly generated structural work in 2023–2024; however, this remains highly authoritative for core NAC biology and directly addresses subcellular localization and molecular mechanism. (zheng2022thenascentpolypeptideassociated pages 1-2)


References

1. (zheng2022thenascentpolypeptideassociated pages 1-2): Alice J L Zheng, Aikaterini Thermou, Chrysoula Daskalogianni, Laurence Malbert-Colas, Konstantinos Karakostis, Ronan Le Sénéchal, Van Trang Dinh, Maria C Tovar Fernandez, Sébastien Apcher, Sa Chen, Marc Blondel, and Robin Fahraeus. The nascent polypeptide-associated complex (nac) controls translation initiation in cis by recruiting nucleolin to the encoding mrna. Nucleic Acids Research, 50:10110-10122, Sep 2022. URL: https://doi.org/10.1093/nar/gkac751, doi:10.1093/nar/gkac751. This article has 8 citations and is from a highest quality peer-reviewed journal.

2. (wang2021molecularcharacterizationof pages 1-2): Han-tao Wang, Junjie Xing, Wei Wang, Guifen Lv, Haiyan He, Yeqing Lu, Mei Sun, Haiyan Chen, and Xu Li. Molecular characterization of the oncogene btf3 and its targets in colorectal cancer. Frontiers in Cell and Developmental Biology, Feb 2021. URL: https://doi.org/10.3389/fcell.2020.601502, doi:10.3389/fcell.2020.601502. This article has 12 citations.

3. (zheng2022thenascentpolypeptideassociated media 2bfdbb98): Alice J L Zheng, Aikaterini Thermou, Chrysoula Daskalogianni, Laurence Malbert-Colas, Konstantinos Karakostis, Ronan Le Sénéchal, Van Trang Dinh, Maria C Tovar Fernandez, Sébastien Apcher, Sa Chen, Marc Blondel, and Robin Fahraeus. The nascent polypeptide-associated complex (nac) controls translation initiation in cis by recruiting nucleolin to the encoding mrna. Nucleic Acids Research, 50:10110-10122, Sep 2022. URL: https://doi.org/10.1093/nar/gkac751, doi:10.1093/nar/gkac751. This article has 8 citations and is from a highest quality peer-reviewed journal.

4. (wang2021molecularcharacterizationof pages 2-4): Han-tao Wang, Junjie Xing, Wei Wang, Guifen Lv, Haiyan He, Yeqing Lu, Mei Sun, Haiyan Chen, and Xu Li. Molecular characterization of the oncogene btf3 and its targets in colorectal cancer. Frontiers in Cell and Developmental Biology, Feb 2021. URL: https://doi.org/10.3389/fcell.2020.601502, doi:10.3389/fcell.2020.601502. This article has 12 citations.

5. (wang2021molecularcharacterizationof pages 6-7): Han-tao Wang, Junjie Xing, Wei Wang, Guifen Lv, Haiyan He, Yeqing Lu, Mei Sun, Haiyan Chen, and Xu Li. Molecular characterization of the oncogene btf3 and its targets in colorectal cancer. Frontiers in Cell and Developmental Biology, Feb 2021. URL: https://doi.org/10.3389/fcell.2020.601502, doi:10.3389/fcell.2020.601502. This article has 12 citations.

6. (zheng2022thenascentpolypeptideassociated pages 8-8): Alice J L Zheng, Aikaterini Thermou, Chrysoula Daskalogianni, Laurence Malbert-Colas, Konstantinos Karakostis, Ronan Le Sénéchal, Van Trang Dinh, Maria C Tovar Fernandez, Sébastien Apcher, Sa Chen, Marc Blondel, and Robin Fahraeus. The nascent polypeptide-associated complex (nac) controls translation initiation in cis by recruiting nucleolin to the encoding mrna. Nucleic Acids Research, 50:10110-10122, Sep 2022. URL: https://doi.org/10.1093/nar/gkac751, doi:10.1093/nar/gkac751. This article has 8 citations and is from a highest quality peer-reviewed journal.

7. (wang2023btf3promotesproliferation pages 1-2): Peng Wang, Jian-Min Sun, Chengming Sun, Haoran Zhao, Yubao Zhang, and Jing Chen. Btf3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating glut1. Cancer Biology & Therapy, Jun 2023. URL: https://doi.org/10.1080/15384047.2023.2225884, doi:10.1080/15384047.2023.2225884. This article has 23 citations and is from a peer-reviewed journal.

8. (wang2023btf3promotesproliferation pages 2-3): Peng Wang, Jian-Min Sun, Chengming Sun, Haoran Zhao, Yubao Zhang, and Jing Chen. Btf3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating glut1. Cancer Biology & Therapy, Jun 2023. URL: https://doi.org/10.1080/15384047.2023.2225884, doi:10.1080/15384047.2023.2225884. This article has 23 citations and is from a peer-reviewed journal.

9. (kong2024btf3affectshepatocellular pages 1-2): Minyu Kong, Xiaoyi Shi, Jie Gao, and Wenzhi Guo. Btf3 affects hepatocellular carcinoma progression by transcriptionally upregulating pdcd2l and inactivating p53 signaling. Molecular Medicine, Dec 2024. URL: https://doi.org/10.1186/s10020-024-01044-x, doi:10.1186/s10020-024-01044-x. This article has 4 citations and is from a peer-reviewed journal.

10. (kong2024btf3affectshepatocellular pages 12-13): Minyu Kong, Xiaoyi Shi, Jie Gao, and Wenzhi Guo. Btf3 affects hepatocellular carcinoma progression by transcriptionally upregulating pdcd2l and inactivating p53 signaling. Molecular Medicine, Dec 2024. URL: https://doi.org/10.1186/s10020-024-01044-x, doi:10.1186/s10020-024-01044-x. This article has 4 citations and is from a peer-reviewed journal.

11. (tan2024arid5b‐mediatedlinc01128epigenetically pages 1-3): Yuan Tan, Jiao Qiao, Shuo Yang, Qingchen Wang, Hongchao Liu, Qi Liu, Weimin Feng, Boxin Yang, Zhongxin Li, and Liyan Cui. Arid5b‐mediated linc01128 epigenetically activated pyroptosis and apoptosis by promoting the formation of the btf3/stat3 complex in β2gpi/anti‐β2gpi‐treated monocytes. Clinical and Translational Medicine, Jan 2024. URL: https://doi.org/10.1002/ctm2.1539, doi:10.1002/ctm2.1539. This article has 8 citations and is from a peer-reviewed journal.

12. (tan2024arid5b‐mediatedlinc01128epigenetically pages 13-16): Yuan Tan, Jiao Qiao, Shuo Yang, Qingchen Wang, Hongchao Liu, Qi Liu, Weimin Feng, Boxin Yang, Zhongxin Li, and Liyan Cui. Arid5b‐mediated linc01128 epigenetically activated pyroptosis and apoptosis by promoting the formation of the btf3/stat3 complex in β2gpi/anti‐β2gpi‐treated monocytes. Clinical and Translational Medicine, Jan 2024. URL: https://doi.org/10.1002/ctm2.1539, doi:10.1002/ctm2.1539. This article has 8 citations and is from a peer-reviewed journal.

13. (tan2024arid5b‐mediatedlinc01128epigenetically pages 6-8): Yuan Tan, Jiao Qiao, Shuo Yang, Qingchen Wang, Hongchao Liu, Qi Liu, Weimin Feng, Boxin Yang, Zhongxin Li, and Liyan Cui. Arid5b‐mediated linc01128 epigenetically activated pyroptosis and apoptosis by promoting the formation of the btf3/stat3 complex in β2gpi/anti‐β2gpi‐treated monocytes. Clinical and Translational Medicine, Jan 2024. URL: https://doi.org/10.1002/ctm2.1539, doi:10.1002/ctm2.1539. This article has 8 citations and is from a peer-reviewed journal.

14. (mavridou2024integrativeanalysisof pages 7-10): Dimitra Mavridou, Konstantina Psatha, and Michalis Aivaliotis. Integrative analysis of multi-omics data to identify deregulated molecular pathways and druggable targets in chronic lymphocytic leukemia. Journal of Personalized Medicine, 14:831, Aug 2024. URL: https://doi.org/10.3390/jpm14080831, doi:10.3390/jpm14080831. This article has 4 citations.

15. (mavridou2024integrativeanalysisof pages 5-7): Dimitra Mavridou, Konstantina Psatha, and Michalis Aivaliotis. Integrative analysis of multi-omics data to identify deregulated molecular pathways and druggable targets in chronic lymphocytic leukemia. Journal of Personalized Medicine, 14:831, Aug 2024. URL: https://doi.org/10.3390/jpm14080831, doi:10.3390/jpm14080831. This article has 4 citations.

16. (patil2024multifacetedimpactof pages 13-14): Ketki Patil, Elizabeth Johnston, Joseph Novack, Garrett Wallace, Michelle Lin, and S. Balakrishna Pai. Multifaceted impact of hiv inhibitor dapivirine on triple negative breast cancer cells reveals potential entities as targets for novel therapy. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-79789-y, doi:10.1038/s41598-024-79789-y. This article has 3 citations and is from a peer-reviewed journal.

17. (patil2024multifacetedimpactof pages 7-10): Ketki Patil, Elizabeth Johnston, Joseph Novack, Garrett Wallace, Michelle Lin, and S. Balakrishna Pai. Multifaceted impact of hiv inhibitor dapivirine on triple negative breast cancer cells reveals potential entities as targets for novel therapy. Scientific Reports, Dec 2024. URL: https://doi.org/10.1038/s41598-024-79789-y, doi:10.1038/s41598-024-79789-y. This article has 3 citations and is from a peer-reviewed journal.

## Citations

1. zheng2022thenascentpolypeptideassociated pages 1-2
2. wang2021molecularcharacterizationof pages 1-2
3. wang2021molecularcharacterizationof pages 2-4
4. wang2021molecularcharacterizationof pages 6-7
5. patil2024multifacetedimpactof pages 7-10
6. mavridou2024integrativeanalysisof pages 5-7
7. zheng2022thenascentpolypeptideassociated pages 8-8
8. mavridou2024integrativeanalysisof pages 7-10
9. patil2024multifacetedimpactof pages 13-14
10. https://doi.org/10.1080/15384047.2023.2225884
11. https://doi.org/10.1186/s10020-024-01044-x
12. https://doi.org/10.1002/ctm2.1539
13. https://doi.org/10.3390/jpm14080831
14. https://doi.org/10.1038/s41598-024-79789-y
15. https://doi.org/10.1093/nar/gkac751
16. https://doi.org/10.3389/fcell.2020.601502
17. https://doi.org/10.1093/nar/gkac751,
18. https://doi.org/10.3389/fcell.2020.601502,
19. https://doi.org/10.1080/15384047.2023.2225884,
20. https://doi.org/10.1186/s10020-024-01044-x,
21. https://doi.org/10.1002/ctm2.1539,
22. https://doi.org/10.3390/jpm14080831,
23. https://doi.org/10.1038/s41598-024-79789-y,